This program provides a comprehensive update for Q4 of 2023 examining the latest developments and trends shaping the landscape of Antitrust Law and Health Care & Pharmaceuticals in both the United States and the European Union.
This program will cover recent U.S. litigation developments, including the Ninth Circuits reversal of Biosense Tying Claims, the FTC’s commentary on the Viatris lawsuit against Sanofi, and the courts decision on whether the American Red Cross is immune from antitrust claims. Panelists also cover recent investigations by the FTC and the European Commission.
This program will also cover recent merger enforcement updates and policy changes for both the United States and European Union. Panelists recap the European Commissions Novozymes-Chr. Hansen merger investigation, Sanofi and Maze merger which was terminated following an FTC administrative complaint, and the Pfizer acquisition of Seagen biotechnology company.
To conclude the program, panelists will review the DOJ and FTC final version of the Merger Guidelines, the FTC’s Orange Book Investigation, and the Amgen/Horizon and USAP fall out.
The content of this program does not meet requirements for continuing legal education (CLE) accreditation. You will not receive CLE credit for participating.
